NewLink Genetics Corp. (NASDAQ:NLNK) shares traded down 4.5% during mid-day trading on Tuesday . The company traded as low as $10.38 and last traded at $10.41, with a volume of 103,869 shares trading hands. The stock had previously closed at $10.90.

A number of research analysts have recently issued reports on the company. Mizuho dropped their target price on NewLink Genetics Corp. from $52.00 to $20.00 and set a “buy” rating on the stock in a report on Tuesday, May 10th. Robert W. Baird reissued an “outperform” rating and issued a $23.00 target price (down previously from $27.00) on shares of NewLink Genetics Corp. in a report on Tuesday, May 10th. Stifel Nicolaus dropped their target price on NewLink Genetics Corp. from $63.00 to $23.00 and set a “buy” rating on the stock in a report on Tuesday, May 10th. Cantor Fitzgerald reissued a “buy” rating and issued a $62.00 target price on shares of NewLink Genetics Corp. in a report on Friday, April 29th. Finally, Zacks Investment Research raised NewLink Genetics Corp. from a “hold” rating to a “buy” rating and set a $13.00 target price on the stock in a report on Tuesday, July 5th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $23.29.

The firm’s market cap is $322.95 million. The firm’s 50 day moving average price is $11.14 and its 200-day moving average price is $17.40.

NewLink Genetics Corp. (NASDAQ:NLNK) last released its earnings results on Friday, April 29th. The company reported ($0.82) EPS for the quarter, topping analysts’ consensus estimates of ($1.70) by $0.88. The firm had revenue of $4.34 million for the quarter, compared to the consensus estimate of $2.08 million. Analysts anticipate that NewLink Genetics Corp. will post ($2.83) EPS for the current year.

A number of hedge funds and institutional investors have recently added to or reduced their stakes in the company. California State Teachers Retirement System increased its position in NewLink Genetics Corp. by 1.7% in the fourth quarter. California State Teachers Retirement System now owns 38,523 shares of the company’s stock worth $1,402,000 after buying an additional 636 shares in the last quarter. EQIS Capital Management increased its position in NewLink Genetics Corp. by 587.5% in the fourth quarter. EQIS Capital Management now owns 41,644 shares of the company’s stock worth $1,515,000 after buying an additional 35,587 shares in the last quarter. Dimensional Fund Advisors LP increased its position in NewLink Genetics Corp. by 0.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 48,507 shares of the company’s stock worth $1,765,000 after buying an additional 300 shares in the last quarter. Cornerstone Capital Management Holdings LLC. increased its position in NewLink Genetics Corp. by 134.1% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 54,775 shares of the company’s stock worth $1,993,000 after buying an additional 31,375 shares in the last quarter. Finally, GSA Capital Partners LLP increased its position in NewLink Genetics Corp. by 5.6% in the fourth quarter. GSA Capital Partners LLP now owns 65,571 shares of the company’s stock worth $2,386,000 after buying an additional 3,498 shares in the last quarter.

NewLink Genetics Corporation is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute immunotherapy technology platform, which is designed to stimulate the human immune system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.